未登录

J

Jane Knöchel

AstraZeneca

H指数:9

被引数:302

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of Epidermal Growth Factor-Like 7 as a Potential Non-Invasive Biomarker for Fibrosis and Mortality Risk in MASLD

表皮生长因子样蛋白7作为MASLD中纤维化和死亡风险的潜在非侵入性生物标志物的发现

CTS-Clinical and Translational Science

IF2.8

2026-09-230

OAAI

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis

cpt: pharmacometrics & systems pharmacology

IF0

2026-01-210

OAAI

The Advance of In Silico Evidence to Transform Pediatric Drug Development for Rare Diseases

基于计算机模拟证据的进展：变革罕见病儿童药物开发

CPT: Pharmacometrics & Systems Pharmacology

IF0

2025-11-180

OAAI

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices

临床药理学中的预测性人工智能：呼吁采取行动，开发稳健的基准测试实践

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-11-010

OAAI

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3

模型指导药物开发的案例研究：一种新型PCSK9反义寡核苷酸。第二部分：从II期到III期

cpt pharmacometrics systems pharmacology

IF0

2025-08-050

OAAI

Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients

转型儿科罕见病药物研发：利用虚拟患者提升临床试验和监管证据

cpt pharmacometrics systems pharmacology

IF0

2025-08-040

OAAI

Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-11-180

OA

Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-08-181

OA

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-06-031

OA

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-03-192

OA

A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-10-031

OA

Deriving mechanism-based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-03-037

OAAI

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

INTERNATIONAL JOURNAL OF CARDIOLOGY

IF3.2

2022-10-018

OAAI

A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-10-016

OAAI

Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans

HEPATOLOGY COMMUNICATIONS

IF4.6

2022-07-1410

OAAI

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-06-1010

OAAI

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

KIDNEY INTERNATIONAL REPORTS

IF5.7

2021-11-019

OAAI

An oral antisense oligonucleotide for PCSK9 inhibition

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2021-05-1289

PRE

Gennemark, Peter; Walter, Katrin; Clemmensen, Niclas; Rekic, Dinko; Nilsson, Catarina A. M.; Knochel, Jane; Holtta, Mikko; Wernevik, Linda; Rosengren, Birgitta; Kakol-Palm, Dorota; Wang, Yanfeng; Yu, Rosie Z.; Geary, Richard S.; Riney, Stan J.; Monia, Brett P.; Isaksson, Rikard; Jansson-Lofmark, Rasmus; Rocha, Cristina S. J.; Linden, Daniel; Hurt-Camejo, Eva; Crooke, Rosanne; Tillman, Lloyd; Ryden-Bergsten, Tina; Carlsson, Bjorn; Andersson, Ulf; Elebring, Marie; Tivesten, Anna; Davies, Nigel